The space renaissance newsletter: WE’RE ALMOST EIGHT BILLIONS: NOTHING CAN STOP US!
Why are governments useful in times of big crisis? Because they can recover the economy, printing currency, supporting stock markets after catastrophic events, such as pandemics.
Senolitics can be one of the first for one of the causes of ageing. One of the agents that have shown a senolytic effect is fisetin.
Because of the availability and safety of fisetin, we decided to conduct our experiments of this drug in a person with autoimmune thyroiditis. It is noteworthy that, unlike most trials, we focus not on chronic inflammation but on immune function.
For this test, we need your financial help.
In recent years, clinical trials of drugs that affect extracellular and intracellular damage leading to ageing of the body have begun. You can find more info here [1].
For example, with age, senescent cells accumulate in our body. They cannot perform their functions normally, their abnormal metabolism is the cause of chronic inflammation, which plays an important role in ageing.
Relatively recently, senolitics, substances that selectively induce apoptosis (lead to programmed death) of senescent cells, have begun to be studied. Their studies have shown that when senescent cells are destroyed in old mice, they begin to look younger, and the function of their body improves.
Hong Kong’s government announced in late February that it would be giving every resident over the age of 18 a cash payout of 10,000 Hong Kong dollars, part of a package of measures aimed at reducing the financial blow to the territory from the COVID-19 outbreak and months of anti-government protests. At the time, the city’s Financial Secretary Paul Chan told CNBC the move could boost Hong Kong’s economy by around 1%.
The U.S. should follow Hong Kong’s lead and give a cash handout to its citizens amid the coronavirus pandemic, a strategist told CNBC Friday.
“This is not a financial crisis,” Andrew Freris, CEO of Ecognosis Advisory, told CNBC’s “Capital Connection.” “It is a crisis about the real economy.”
He noted that in 2008, central banks used stimulus to respond to the collapse of the U.S. mortgage market — but he said nothing of the kind was happening right now.
The Federal Reserve swept into action on Sunday in a new bid to save the U.S. economy from the fallout of the coronavirus, cutting its benchmark interest rate by a full percentage point to near zero and promising to boost its bond holdings by at least $700 billion.
The central bank also announced several other actions, including letting banks borrow from the discount window for as long as 90 days and reducing reserve requirement ratios to zero percent. In addition, the Fed united with five other central banks to ensure dollars are available around the world via swap lines.
Fed Chairman Jerome Powell will hold a press conference at 6:30 p.m. Washington time to discuss the actions.
Coronavirus’s economic danger is exponentially greater than its health risks to the public. If the virus does directly affect your life, it is most likely to be through stopping you going to work, forcing your employer to make you redundant, or bankrupting your business.
The trillions of dollars wiped from financial markets this week will be just the beginning, if our governments do not step in. And if President Trump continues to stumble in his handling of the situation, it may well affect his chances of re-election. Joe Biden in particular has identified Covid-19 as a weakness for Trump, promising “steady, reassuring” leadership during America’s hour of need.
© Provided by The Independent Worldwide, Covid-19 has killed 4,389 with 31 US deaths as of today. But it will economically cripple millions, especially since the epidemic has formed a perfect storm with stock market crashes, an oil war between Russia and Saudi Arabia, and the spilling over of an actual war in Syria into another potential migrant crisis.
The scientific revolution was ushered in at the beginning of the 17th century with the development of two of the most important inventions in history — the telescope and the microscope. With the telescope, Galileo turned his attention skyward, and advances in optics led Robert Hooke and Antonie van Leeuwenhoek toward the first use of the compound microscope as a scientific instrument, circa 1665. Today, we are witnessing an information technology-era revolution in microscopy, supercharged by deep learning algorithms that have propelled artificial intelligence to transform industry after industry.
One of the major breakthroughs in deep learning came in 2012, when the performance superiority of a deep convolutional neural network combined with GPUs for image classification was revealed by Hinton and colleagues [1] for the ImageNet Large Scale Visual Recognition Challenge (ILSVRC). In AI’s current innovation and implementation phase, deep learning algorithms are propelling nearly all computer vision-intensive applications, including autonomous vehicles (transportation, military), facial recognition (retail, IT, communications, finance), biomedical imaging (healthcare), autonomous weapons and targeting systems (military), and automation and robotics (military, manufacturing, heavy industry, retail).
It should come as no surprise that the field of microscopy would ripe for transformation by artificial intelligence-aided image processing, analysis and interpretation. In biological research, microscopy generates prodigious amounts of image data; a single experiment with a transmission electron microscope can generate a data set containing over 100 terabytes worth of images [2]. The myriad of instruments and image processing techniques available today can resolve structures ranging in size across nearly 10 orders of magnitude, from single molecules to entire organisms, and capture spatial (3D) as well as temporal (4D) dynamics on time scales of femtoseconds to seconds.
More than 2000 Australian suffering from advanced melanoma will soon receive financial relief with an expansion of treatments on the Pharmaceutical Benefits Scheme, federal Health Minister Greg Hunt says.
From March 1 the PBS listed Opdivo (nivolumab) will be expanded, assisting 1500 patients who might otherwise pay more than $100,000 per course of treatment without the PBS subsidy.
“Opdivo is a breakthrough immunotherapy which works by blocking proteins and helping the body’s own immune system to find, attack and destroy cancer cells,” Mr Hunt said in a statement on Sunday.
Stocks cratered again on Tuesday, hitting their sessions lows after a CDC official told the U.S. to brace for a possible breakout of coronavirus here.
In this post, you’ll find why I think SENS Research Foundation (SRF) is great to finance from an EA perspective along with the interview questions I want to ask its Chief Science Officer, Aubrey de Grey. You are welcome to contribute with your own questions in the comments or through a private message. Here is a brief summary of each section:
Introduction: Aging research looks extremely good as a cause-area from an EA perspective. Under a total utilitarian view, it is probably second or third after existential risk mitigation. There are many reasons why it makes sense to donate to many EA cause-areas, such as to reduce risk, if there are particularly effective specific interventions, or if some cause-areas are already well funded.
SRF’s approach to aging research: SRF selects its research following the SENS general strategy, which divides aging into seven categories of damage, each having a corresponding line of research. This categorization is very similar to the one described in the landmark paper The Hallmarks of Aging. This sort of damage repair approach seems more effective and tractable than current geriatrics and biogerontology that are aimed at slowing down aging, as it enables LEV and many more QALYs. It makes rejuvenation possible instead of just slowing down aging as a best-case scenario, and it doesn’t require an in-depth knowledge of our metabolism, which is extremely complicated and full of unknown-unknowns.
